COLONG: Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib
Phase of Trial: Phase IV
Latest Information Update: 22 May 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms COLONG
- Sponsors Bayer
- 31 Aug 2018 Biomarkers information updated
- 14 May 2018 Status changed from recruiting to completed.
- 09 Mar 2018 Status changed from not yet recruiting to recruiting.